2
26
TMS or methyl protecting groups of 2 suffered from low yield due to competative hydrostannylation of
the triple bond.
Allylic oxidation of 3 with SeO in 1,4-dioxane in the presence of acetic acid gave out aldehyde 4
2
(
29% for 4a and 69% for 4b) presumably through hemiacetal intermediate (Scheme 2). When treated
4
with pyridinium dichromate in DMF, the aldehydes 4 were further oxidized to lactones 5 (30% and
7
the known precursor of showdomycin syntheses, under ozonolysis and reductive cleavage.
5
4%, respectively), through hemiacetal intermediate also, which could be converted to 6 in 19% yield,
6
Scheme 2.
Transformation of the aldehyde intermediates 4 to a pyrazine C-glycoside derivative was performed
by ozonolysis and reductive cleavage to yield α-keto aldehyde intermediate, which was reacted with 1,2-
4
phenylenediamine without purification. Compound 7 was obtained in 21% yield from 4a and 52% from
4
4
b, respectively. Deprotection of 7 in a 4:1 mixture of CF CO H and H O provided 8 in 41% yield.
3
2
2
In summary, the radical cyclization reaction of ribofuranose intermediate 2 suggests a new C-
glycosylation route for C-glycoside derivatives.
Acknowledgements
This research was financially supported by the Ministry of Education through the Basic Science
Research Institute Program (BSRI-98-3433).
References
1
2
. Jaramillo, C.; Knapp, S. Synthesis 1994, 1–20. (b) Postema, M. H. D. C-Glycoside Synthesis; CRC Press: Boca Raton, 1995.
. Yahiro, Y.; Ichikawa, S.; Shuto, S.; Matsuda, A. Tetrahedron Lett. 1999, 40, 5527–5531. (b) De Mesmaeker, A.; Waldner, A.;
Hoffmann, P.; Winkler, T. Synlett 1994, 330–332. (c) Kim, G.; Kang, S.; Kim, S. N. Tetrahedron Lett. 1993, 37, 7627–7628.
(d) Stork, G.; Suh, H. S.; Kim, G. J. Am. Chem. Soc. 1991, 113, 7054–7055.
3
4
. The products are mixtures of E/Z isomers in a ca. 1:1 to 4:3 ratio. Following reactions were carried out with the mixtures.
−
1 1
. Compound 5a (one isomer): IR (CDCl
3
) 1732, 1379, 1371,1251 cm ; H NMR (300 MHz, CDCl
3
) 6.49 (s, 1H), 4.91 (d,
1
9
H, J=5.7 Hz), 4.65 (d, 1H, J=5.7 Hz), 4.55 (s, 1H), 4.37 (m, 1H), 4.15–4.21 (m, 2H), 1.49 (s, 3H), 1.30 (s, 3H), 0.14 (s,
13
H); C NMR (75 MHz, CDCl
3
) 169.1, 151.3, 146.3, 112.3, 87.4, 83.4, 81.8, 81.5, 71.5, 25.9, 24.2, −1.2 (×3); m/z 283
). 7: H NMR (300 MHz, CDCl ) 8.91 (s, 1H), 8.02–8.16 (m, 2H), 7.75–7.83 (m, 2H), 5.38 (d, 1H, J=3.4 Hz),
.92–4.98 (m, 2H), 4.56 (dt, 1H, J=2.4, 2.3 Hz), 4.04 (dd, J=12.4, 2.4 Hz), 3.75 (dd, 1H, J=12.4, 2.7 Hz), 1.60 (s, 3H), 1.40
+
1
(
4
M −CH
3
3
+
25
1
(
8
s, 3H); m/z 287 (M −CH
3
); [α]
D
3
=−7.89 (c=0.015, MeOH). Compound 8: H NMR (400 MHz, CD OD) 9.12 (s, 1H),
.07–8.10 (m, 2H), 7.81–7.87 (m, 2H), 5.10 (d, 1H, J=5.6 Hz), 4.31 (dd, 1H, J=5.6, 5.2 Hz), 4.20 (dd, 1H, J=5.20, 5.20 Hz),